FAROSAR H

Indications

• Hypertension
• Chronic heart failure when ACE inhibitors are unsuitable
• Diabetic nephropathy in type 2 diabetes mellitus

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Initially 50 mg once daily for adults aged 18–75 years, and 25 mg once daily for adults aged 76 years and over. Doses may be increased to 100 mg once daily if necessary.

Mechanism of action

Losartan selectively blocks the binding of angiotensin II to the AT1 receptor, leading to vasodilation, decreased secretion of aldosterone, and reduced blood pressure. This mechanism also contributes to renal protection in diabetic patients by reducing glomerular pressure.

Pharmacodynamics

Losartan exhibits dose-dependent antihypertensive effects, with initial doses often resulting in a reduction of blood pressure within 6 hours. The peak effect is typically reached within 4 to 6 weeks of treatment. Additionally, losartan has a protective effect on renal function in patients with diabetic nephropathy.

Pharmacokinetics

Losartan is well absorbed after oral administration, with a bioavailability of approximately 33%. It is extensively metabolized in the liver to its active metabolite, E3174, which has a longer half-life than losartan itself. The elimination half-life of losartan is around 2 hours, while that of E3174 is approximately 6 to 9 hours. Both losartan and E3174 are primarily excreted in the urine, and renal impairment may affect their clearance.

Contra-indications

• Hypersensitivity to losartan or any of the excipients
• Severe hepatic impairment
• Pregnancy
• Bilateral renal artery stenosis or unilateral renal artery stenosis in a solitary kidney
• History of angioedema

Adverse effects

• Dizziness
• Hypotension
• Hyperkalaemia
• Fatigue
• Postural hypotension
• Abdominal pain
• Nausea
• Diarrhoea
• Headache
• Musculoskeletal pain
• Renal impairment

Interactions

• Other antihypertensive agents may enhance the hypotensive effect
• Potassium supplements or potassium-sparing diuretics may increase the risk of hyperkalaemia
• Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect
• Lithium levels may be increased when taken with losartan

Precautions

• Monitor renal function and electrolytes in patients with renal impairment
• Use with caution in patients with a history of angioedema
• Caution in patients with volume depletion
• Not recommended for use in patients with severe heart failure

Pregnancy

Losartan is contraindicated in pregnancy due to potential harm to the fetus, particularly during the second and third trimesters.

Breast-feeding

It is not known whether losartan is excreted in human milk; caution is advised when administering to breastfeeding women.

Storage

Store at room temperature (15 to 30 degrees Celsius), protected from light and moisture.

Formulations

• Losartan potassium 12.5 mg tablets
• Losartan potassium 25 mg tablets
• Losartan potassium 50 mg tablets
• Losartan potassium 100 mg tablets
• Losartan with hydrochlorothiazide 50 mg/12.5 mg tablets
• Losartan with hydrochlorothiazide 100 mg/12.5 mg tablets

Indications

• Hypertension
• Edema associated with congestive heart failure
• Edema due to renal dysfunction

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: 2.5 mg daily, taken in the morning for hypertension; higher doses may be used for other indications.

Mechanism of action

Hydrochlorothiazide is transported into epithelial cells of the distal convoluted tubule via organic anion transporters OAT1, OAT3, and OAT4. It inhibits the sodium-chloride symporter (SLC12A3), preventing sodium reabsorption. This action reduces the concentration gradient that promotes water reabsorption, leading to increased urine production.

Pharmacodynamics

Hydrochlorothiazide increases the excretion of sodium and water, thereby promoting diuresis. It is effective in lowering blood pressure and has a wide therapeutic range, with doses typically ranging from 25 to 100 mg. The drug exhibits a greater antihypertensive effect at lower doses due to enhanced vasodilation, while higher doses primarily exert their effects through diuresis. Caution is advised in patients with renal or hepatic impairment.

Pharmacokinetics

Hydrochlorothiazide is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-2 hours post-administration. It has a half-life of about 6-15 hours, depending on individual patient factors. The drug is primarily excreted unchanged in the urine. Dosage adjustments may be necessary in patients with renal impairment due to the risk of accumulation.

Contra-indications

• History of hypersensitivity to sulfonamides
• Acute porphyrias
• Severe renal impairment

Adverse effects

• Angina pectoris
• Arrhythmias
• Arthralgia
• Asthenia
• Chest pain
• Confusion
• Dry mouth
• Haemolytic anaemia
• Hepatic disorders
• Hyperkalaemia
• Hypokalemia
• Nausea
• Rhabdomyolysis
• Syncope
• Vertigo

Interactions

• Potassium-sparing diuretics
• Other antihypertensives
• Lithium
• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Corticosteroids

Precautions

• Diabetes mellitus
• Elderly patients
• Basal cell carcinoma
• Cutaneous lupus erythematosus
• Patients with hepatic impairment
• Monitoring of electrolytes

Pregnancy

Hydrochlorothiazide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is advisable to avoid use, especially during the first trimester.

Breast-feeding

Hydrochlorothiazide is present in breast milk; however, the amount is probably too small to be harmful. Caution is advised as large doses may suppress lactation.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Tablets: 12.5 mg, 25 mg
• Oral solution
• Combination products with amiloride

Indications

• Hypovolemic shock
• Severe burns
• Postoperative fluid replacement
• Sepsis
• Trauma management

Dosage

Children: Refer to established guidelines for specific dosing, as it varies based on the type of colloidal solution used and the clinical condition being treated.

Adults: Refer to established guidelines for specific dosing, as it varies based on the type of colloidal solution used and the clinical condition being treated.

Mechanism of action

Colloidal solutions work by maintaining oncotic pressure in the blood, thus helping to retain fluid within the vascular system. This is primarily due to the large molecular weight of the colloidal particles, which cannot easily pass through capillary walls. The presence of colloids in the blood helps to draw water into the circulation, increasing blood volume and improving tissue perfusion.

Pharmacodynamics

The pharmacodynamics of colloidal solutions are centered on their ability to exert osmotic pressure, which helps maintain blood volume and pressure. This effect is particularly important in conditions such as hypovolemia and shock, where fluid replacement is necessary to restore hemodynamic stability. The efficacy of colloidal solutions can vary depending on the type of colloid used, as well as the underlying clinical condition being treated.

Pharmacokinetics

Colloidal solutions are typically administered intravenously and their pharmacokinetics can vary based on the specific formulation. Generally, colloids are distributed throughout the vascular compartment and have a longer duration of action compared to crystalloids, as they remain in circulation longer. The elimination of colloids is primarily through the reticuloendothelial system, where they are metabolized or eliminated by the liver and spleen. Factors such as particle size and composition can influence their distribution and clearance.

Adverse effects

• Allergic reactions
• Injection site reactions
• Nausea
• Vomiting
• Headache
• Fever

Precautions

• Use with caution in patients with known allergies to any component of the formulation
• Monitor for signs of hypersensitivity during administration
• Consider volume overload in patients with cardiac or renal impairment

Pregnancy

The safety of colloidal solutions during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether colloidal solutions are excreted in human milk. Caution should be exercised when administering to breastfeeding mothers.

Storage

Store at room temperature, protect from light, and do not freeze. Keep out of reach of children.

Formulations

• Colloidal silver
• Colloidal gold
• Colloidal iron
• Other metal colloids

Dosage

Children: Refer to specific clinical guidelines or consult a pediatric specialist for appropriate dosing information.

Adults: Refer to specific clinical guidelines or consult a prescribing physician for appropriate dosing information.

Mechanism of action

The exact mechanism of action of creostum is not well-defined in the available literature. However, it may involve modulation of neurotransmitter systems and pathways associated with neuroprotection and anti-inflammatory effects.

Pharmacodynamics

Pharmacodynamics for creostum may involve interactions with specific receptors or pathways that influence neuronal health and function. The drug might exhibit neuroprotective properties, impacting various cellular processes such as apoptosis, oxidative stress, and inflammation.

Pharmacokinetics

Detailed pharmacokinetic parameters for creostum, including absorption, distribution, metabolism, and excretion (ADME) profiles, are not extensively documented. Further studies are needed to elucidate how the drug behaves in the body and its half-life.

Pregnancy

The safety of creostum in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether creostum is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Indications

• Monitoring respiratory function
• Assessment of metabolic status
• Management of respiratory acidosis
• Management of respiratory alkalosis

Dosage

Children: Dosing for interventions related to carbon dioxide levels in pediatric patients should be guided by clinical protocols and the BNF for Children.

Adults: Dosing for interventions related to carbon dioxide levels is typically based on clinical assessment and individual patient needs. Refer to clinical guidelines for specific scenarios.

Mechanism of action

Carbon dioxide acts primarily as a signaling molecule in the body, influencing respiratory drive and blood pH. It is produced during cellular respiration and is a critical component of the bicarbonate buffering system, which helps maintain acid-base homeostasis. Elevated levels of CO2 in the blood stimulate ventilation in the lungs, increasing the rate of gas exchange and facilitating the removal of excess CO2.

Pharmacodynamics

The pharmacodynamic effects of dioxides, particularly carbon dioxide, are closely related to its concentration in the blood. As CO2 levels increase, it leads to respiratory acidosis, which can stimulate the respiratory centers in the brain to increase ventilation. Conversely, low levels of CO2 can cause respiratory alkalosis, potentially leading to decreased respiratory drive. CO2 also plays a role in vasodilation and can affect blood flow and pressure through its influence on smooth muscle tone.

Pharmacokinetics

Carbon dioxide is produced endogenously during metabolic processes and is transported in the bloodstream primarily in three forms: dissolved in plasma, as bicarbonate ions (HCO3-), and bound to hemoglobin. The half-life of CO2 in the bloodstream is very short due to its rapid exchange with alveolar gas in the lungs. The elimination of CO2 occurs through exhalation, making it a dynamic component of respiratory physiology.

Pregnancy

Data on the effects of dioxide during pregnancy are limited. Caution is advised due to potential risks associated with exposure.

Breast-feeding

Limited data are available regarding the excretion of dioxide in human milk. Caution is recommended.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Nutritional supplementation
• Herbal therapy for various conditions
• Preservation of medicinal properties of plants

Dosage

Children: Dosage for dried herbal preparations in children should be approached cautiously and is best determined by a healthcare professional. Refer to paediatric guidelines for specific dosing recommendations.

Adults: Dosage for dried herbal preparations varies widely depending on the specific herb and its intended use. Refer to specific guidelines or reputable sources for dosing information.

Mechanism of action

The mechanism of action for dried herbal preparations varies depending on the specific plant material involved. Generally, the active constituents in dried herbs can exert their effects through various pathways, such as modulating neurotransmitter systems, influencing metabolic pathways, and acting on specific receptors in the body. For instance, flavonoids, terpenes, and alkaloids found in certain dried herbs can exhibit anti-inflammatory, antioxidant, or antimicrobial properties.

Pharmacodynamics

The pharmacodynamics of dried drugs depend on their specific chemical constituents. These compounds can affect physiological functions, such as modulating inflammatory responses, enhancing immune function, or affecting neurotransmission. The effects can vary widely based on the type of herb, the method of drying, and the concentration of active ingredients.

Pharmacokinetics

The pharmacokinetics of dried herbal preparations can vary significantly based on the specific herb used. Generally, after ingestion, the active compounds are absorbed in the gastrointestinal tract, metabolized primarily by the liver, and then excreted through urine or feces. The bioavailability of these compounds can be influenced by factors such as the form of the preparation (e.g., powder, extract), the presence of other food substances, and individual patient characteristics.

Pregnancy

Safety during pregnancy has not been established. Consult a healthcare provider before use.

Breast-feeding

Consult a healthcare provider before use during breastfeeding.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Hypertension
• Diabetic nephropathy
• Reduction of stroke risk in certain populations

Dosage

Children: For paediatric patients aged 6 years and older, the starting dose is usually 0.7 mg/kg once daily, with a maximum of 50 mg daily. Dosing should be adjusted based on blood pressure response and tolerance.

Adults: The typical adult dose for hypertension is 50 mg once daily, which may be increased to a maximum of 100 mg once daily, depending on response.

Mechanism of action

Losartan reversibly and competitively prevents angiotensin II from binding to the AT1 receptor in various tissues, including vascular smooth muscle and the adrenal gland. By doing so, it causes relaxation of vascular smooth muscle, leading to decreased blood pressure. Losartan's active metabolite is significantly more potent as an AT1 receptor inhibitor and further enhances the drug's efficacy in blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.

Pharmacodynamics

Losartan is classified as an angiotensin II receptor blocker that effectively lowers blood pressure and is indicated for diabetic nephropathy. It has a long duration of action, which supports its once-daily administration. Regular monitoring of patients is recommended to assess for hypotension, renal function, and potassium levels, as the drug can affect these parameters.

Pharmacokinetics

Losartan is well absorbed and undergoes extensive first-pass metabolism, resulting in an active metabolite that contributes to its therapeutic effects. The drug is primarily eliminated through the urine and feces. The half-life of losartan and its active metabolite allows for stable plasma concentrations with once-daily dosing, but renal impairment may affect its clearance.

Contra-indications

• Hypersensitivity to losartan or any of its excipients
• Severe hepatic impairment
• Pregnancy

Adverse effects

• Dizziness
• Hypotension
• Hyperkalemia
• Renal impairment
• Fatigue
• Headache
• Diarrhea

Interactions

• Potassium-sparing diuretics may increase the risk of hyperkalemia
• Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect of losartan
• Lithium levels may increase when used concurrently with losartan

Precautions

• Monitor blood pressure regularly
• Assess renal function before and during treatment
• Caution in patients with a history of angioedema
• Use with caution in patients with renal artery stenosis

Pregnancy

Losartan is contraindicated in pregnancy due to potential harm to the fetus.

Breast-feeding

Losartan is excreted in breast milk, caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place at room temperature, away from direct sunlight.

Formulations

• Tablets: 25 mg, 50 mg, 100 mg

Indications

• Irritable bowel syndrome
• Dyspepsia
• Nausea
• Headaches
• Respiratory congestion

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines.

Adults: Refer to the relevant product-specific information for dosing recommendations, as peppermint formulations can vary widely.

Mechanism of action

The primary active component, menthol, works by activating the TRPM8 (transient receptor potential cation channel subfamily M member 8) ion channel, which is involved in the sensation of cold and cooling. This action can lead to a localized anesthetic effect, reducing pain and discomfort. Additionally, menthol can cause relaxation of smooth muscle in the gastrointestinal tract, aiding in the relief of digestive symptoms.

Pharmacodynamics

Peppermint exhibits antispasmodic effects, particularly in the gastrointestinal tract, by relaxing the smooth muscles. It also has a mild analgesic effect due to its cooling sensation, which can provide symptomatic relief in various conditions. Furthermore, peppermint oil may have antimicrobial properties, contributing to its use in treating certain infections.

Pharmacokinetics

Menthol is rapidly absorbed after oral administration and is metabolized in the liver. The peak plasma concentration typically occurs within a few hours. The elimination half-life of menthol is approximately 1.5 to 2 hours, and it is primarily excreted in the urine as metabolites. The pharmacokinetics of peppermint oil can vary based on the formulation and route of administration.

Interactions

• peppermint oil + lomitapide: Unknown (increases exposure)

Pregnancy

Peppermint is generally considered safe for use in pregnancy when used in culinary amounts. However, high doses should be avoided due to potential uterine stimulation.

Breast-feeding

Peppermint is considered safe during breastfeeding when used in culinary amounts. Caution is advised with high doses as effects on the infant are not well studied.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Peppermint oil
• Peppermint extract
• Peppermint tea

Indications

• Prevention of poliomyelitis infection
• Vaccination in children and high-risk populations

Dosage

Children: Refer to the BNF for Children for specific dosages and recommendations for vaccination schedules.

Adults: Refer to specific vaccination guidelines for adults, as dosages may vary based on risk factors and prior vaccination history.

Mechanism of action

Poliovirus enters the body through the oral route, replicating in the oropharynx and gastrointestinal tract before spreading to the central nervous system via the bloodstream. Once inside the CNS, the virus selectively infects motor neurons in the anterior horn of the spinal cord, leading to cell lysis and resulting in muscle weakness or paralysis. The immune response to the virus contributes to inflammation and further neuronal damage.

Pharmacodynamics

The poliovirus's pathogenicity is primarily due to its ability to evade the host's immune response and its selective neurotropism. The destruction of motor neurons leads to flaccid paralysis, with recovery possible in some cases as the motor neurons may regenerate. The severity of the disease correlates with the extent of neuronal involvement, which can vary widely among individuals.

Pharmacokinetics

Poliovirus is an RNA virus that does not undergo traditional pharmacokinetic processes as it is not treated with drugs. Instead, the prevention of polio relies on vaccination strategies. The inactivated poliovirus vaccine (IPV) and the oral poliovirus vaccine (OPV) are used to induce immunity. After administration, the vaccines promote the development of antibodies against the virus without causing disease.

Contra-indications

• Hypersensitivity to the vaccine component
• Severe immunodeficiency
• Acute febrile illness

Adverse effects

• Pain at injection site
• Fever
• Fatigue
• Headache
• Nausea
• Allergic reactions

Interactions

• Immunosuppressive therapies may reduce vaccine efficacy
• Concomitant administration with other vaccines may affect immune response

Precautions

• Use with caution in individuals with moderate to severe acute illness
• Consider history of allergic reactions
• Monitor for signs of anaphylaxis after administration

Pregnancy

Poliomyelitis vaccination is generally considered safe during pregnancy, but consult a healthcare professional.

Breast-feeding

The vaccine is considered safe for breastfeeding mothers.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Inactivated poliovirus vaccine (IPV)
• Oral poliovirus vaccine (OPV)

Indications

• Hypokalemia
• Management of potassium deficiency
• Prevention of arrhythmias in patients on diuretics
• Certain kidney disorders

Dosage

Children: Refer to pediatric dosing guidelines based on specific indications and clinical context.

Adults: Refer to clinical guidelines for specific dosing adjustments based on individual patient needs and conditions.

Mechanism of action

Potassium ions (K+) are involved in many cellular processes, including the generation of action potentials in neurons and muscle cells. They help maintain the resting membrane potential and are essential for the depolarization and repolarization phases of the cardiac action potential. Potassium also plays a role in enzyme function and the regulation of acid-base balance.

Pharmacodynamics

Potassium's primary action is to facilitate normal muscle function, including cardiac and smooth muscle contraction. It is also critical for nerve impulse conduction. Adequate potassium levels are necessary to prevent complications such as arrhythmias, muscle weakness, and paralysis.

Pharmacokinetics

Potassium is absorbed through the gastrointestinal tract, with the majority being absorbed in the small intestine. The distribution of potassium in the body is primarily within cells, with a small amount present in extracellular fluid. The kidneys play a significant role in regulating potassium levels, excreting excess potassium to maintain homeostasis. The half-life of potassium in the body can vary based on dietary intake, renal function, and other factors.

Contra-indications

• Hyperkalemia
• Severe renal impairment
• Adrenal insufficiency

Adverse effects

• Hyperkalemia
• Cardiac arrhythmias
• Muscle weakness
• Nausea
• Diarrhea

Interactions

• Potassium-sparing diuretics (e.g., spironolactone) may increase potassium levels
• ACE inhibitors and ARBs can lead to elevated potassium levels
• Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce renal clearance of potassium

Precautions

• Monitor serum potassium levels in patients with renal impairment
• Use cautiously in patients with heart disease or on digoxin
• Evaluate dietary potassium intake in patients receiving potassium supplementation

Pregnancy

Potassium is generally considered safe during pregnancy, but high doses should be avoided. Monitoring of potassium levels may be necessary.

Breast-feeding

Potassium is excreted in breast milk, but no adverse effects have been reported. Normal dietary intake is typically safe.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets
• Oral solution
• Intravenous injection
• Intravenous infusion

Dosage

Children: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Adults: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Mechanism of action

The mechanism of action for purified compounds varies widely depending on the specific substance. Generally, purified drugs exert their effects by interacting with specific biological targets, such as receptors, enzymes, or ion channels, leading to a desired therapeutic effect. This interaction can involve binding to receptors to activate or inhibit signaling pathways, modulating enzymatic activity, or altering physiological processes.

Pharmacodynamics

Pharmacodynamics describes the effects of a drug on the body and the relationship between drug concentration and effect. For purified drugs, this can involve dose-response relationships and the time course of their action. The purified form often enhances potency and reduces variability in response among patients, which can lead to more predictable therapeutic outcomes. The overall effect is determined by the drug's affinity for its target, the efficacy of the drug-receptor interaction, and the downstream signaling pathways activated as a result of this interaction.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. For purified substances, absorption can be more efficient due to the absence of impurities that may affect solubility or stability. Distribution may also be enhanced, leading to higher bioavailability. Metabolism can be influenced by the structure of the purified compound, as it may be metabolized more readily by liver enzymes. Excretion typically occurs through the kidneys or liver, depending on the molecular characteristics of the purified drug.

Pregnancy

Consult with a healthcare professional, as the safety of purified forms of medications during pregnancy may vary depending on the specific substance.

Breast-feeding

Consult with a healthcare professional, as the safety of purified forms of medications during breastfeeding may vary depending on the specific substance.

Storage

Store in a cool, dry place, away from light and moisture, and keep out of reach of children.

Indications

• Potential role in bone health
• Support for connective tissue formation
• May aid in mineral metabolism

Dosage

Children: There is no established clinical dosage for silicon in paediatric populations, as it is not classified as an essential nutrient.

Adults: There is no established clinical dosage for silicon in adults, as it is not classified as an essential nutrient.

Mechanism of action

Silicon is believed to enhance the synthesis of glycosaminoglycans and collagen, which are important for the structural integrity of connective tissues. It may also influence the activity of certain enzymes involved in bone mineralization, thus playing a role in maintaining bone density and health.

Pharmacodynamics

The pharmacodynamics of silicon is not fully elucidated; however, it is thought to involve the modulation of bone metabolism and the promotion of connective tissue health. Silicon may have a synergistic effect with other minerals, such as calcium and magnesium, aiding in their utilization and metabolism in the body.

Pharmacokinetics

The pharmacokinetics of silicon is complex, as it is not absorbed through typical gastrointestinal pathways. Instead, silicon is thought to be taken up in the form of silicates and then distributed throughout the body, particularly in connective tissues. The elimination of silicon occurs primarily through renal excretion, with some variations depending on dietary intake and individual metabolism.

Pregnancy

Silicon is generally considered safe during pregnancy, as it is a naturally occurring element in the human body. However, specific recommendations regarding supplementation should be followed based on the advice of a healthcare provider.

Breast-feeding

Silicon is present in breast milk in small amounts. Its safety during breastfeeding is generally regarded as acceptable, although supplementation should be approached with caution and under medical advice.

Storage

Silicon should be stored in a cool, dry place, protected from light and moisture. Follow specific storage recommendations provided by the manufacturer if available.

Indications

• Used as an excipient in drug formulations
• Pleurodesis for the management of recurrent pleural effusions

Dosage

Children: Refer to specific guidelines for paediatric use, as dosing may differ based on age and clinical condition.

Adults: Refer to specific guidelines for the appropriate dosage in pleurodesis and other applications, as it may vary based on clinical context.

Mechanism of action

Talc exhibits very good absorptive properties, allowing it to absorb moisture and other substances effectively. This characteristic is particularly useful in pharmaceutical formulations, where it may enhance the stability and texture of the drug product.

Pharmacodynamics

Talc's primary pharmacodynamic effect is its ability to act as an inert filler and bulking agent in pharmaceutical preparations. It does not have any intrinsic pharmacological activity but serves to improve the physical properties of formulations, such as flowability and compressibility.

Pharmacokinetics

Talc is not absorbed systemically when used as an excipient or in medical procedures. Its effects are local, and it remains in the site of application, where it functions primarily as a mechanical agent. The pharmacokinetics of talc in the context of its use in pleurodesis involves its ability to promote adhesion of the pleural surfaces, thereby preventing fluid accumulation.

Pregnancy

Talc is classified as a substance with minimal systemic absorption, but safety during pregnancy has not been well established. Consult relevant guidelines.

Breast-feeding

Talc is not expected to be absorbed in significant amounts; however, caution is advised and consult guidelines.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.

Indications

• Nutritional supplement
• Support for digestive health
• Enhancement of immune function
• Source of B vitamins

Dosage

Children: Refer to specific product guidelines, as dosage may vary based on formulation and intended use.

Adults: Refer to specific product guidelines, as dosage may vary based on formulation and intended use.

Mechanism of action

Yeast operates through various biochemical pathways, primarily by fermenting sugars to produce alcohol and carbon dioxide. In its role as a dietary supplement, it may enhance gut health by supporting the growth of beneficial gut flora and improving nutrient absorption. Additionally, yeast extract can modulate immune responses and has been studied for its potential antioxidant properties.

Pharmacodynamics

Yeast contains various bioactive compounds, including beta-glucans, which may enhance immune function and exhibit anti-inflammatory properties. The nutrients in yeast, such as B vitamins and amino acids, play crucial roles in metabolic processes, energy production, and overall health maintenance. The fermentation products can also influence gut microbiota composition and enhance digestive health.

Pharmacokinetics

When ingested, yeast components are digested in the gastrointestinal tract where they are broken down into absorbable nutrients. The bioavailability of vitamins and minerals from yeast can vary based on the preparation method. The metabolic byproducts of yeast fermentation are utilized by the body for energy and other metabolic functions. The elimination of yeast components occurs primarily through fecal excretion, as well as through metabolic pathways in the liver.

Adverse effects

• Gastrointestinal discomfort
• Gas and bloating
• Allergic reactions
• Headache

Precautions

• Use with caution in individuals with a compromised immune system
• May cause allergic reactions in sensitive individuals

Pregnancy

Generally considered safe, but consult a healthcare provider before use.

Breast-feeding

Generally considered safe, but consult a healthcare provider before use.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Capsules
• Tablets
• Powder
• Liquid

Mechanism of action

Hydrochlorothiazide is transported from the circulation into epithelial cells of the distal convoluted tubule by the organic anion transporters OAT1, OAT3, and OAT4. From these cells, hydrochlorothiazide is transported to the lumen of the tubule by multidrug resistance associated protein 4 (MRP4). Normally, sodium is reabsorbed into epithelial cells of the distal convoluted tubule and pumped into the basolateral interstitium by a sodium-potassium ATPase, creating a concentration gradient between the epithelial cell and the distal convoluted tubule that promotes the reabsorption of water. Hydrochlorothiazide acts on the proximal region of the distal convoluted tubule, inhibiting reabsorption by the sodium-chloride symporter, also known as Solute Carrier Family 12 Member 3 (SLC12A3). Inhibition of SLC12A3 reduces the magnitude of the concentration gradient between the epithelial cell and distal convoluted tubule, reducing the reabsorption of water.

Pharmacodynamics

Hydrochlorothiazide prevents the reabsorption of sodium and water from the distal convoluted tubule, allowing for the increased elimination of water in the urine. Hydrochlorothiazide has a wide therapeutic window as dosing is individualized and can range from 25-100mg. Hydrochlorothiazide should be used with caution in patients with reduced kidney or liver function.

Mechanism of action

Losartan reversibly and competitively prevents angiotensin II binding to the AT₁ receptor in tissues like vascular smooth muscle and the adrenal gland. Losartan and its active metabolite bind the AT₁ receptor with 1000 times more affinity than they bind to the AT₂ receptor. The active metabolite of losartan is 10-40 times more potent by weight than unmetabolized losartan as an inhibitor of AT₁ and is a non-competitive inhibitor. Losartan's prevention of angiotensin II binding causes vascular smooth muscle relaxation, lowering blood pressure. Angiotensin II would otherwise bind to the AT₁ receptor and induce vasoconstriction, raising blood pressure. Angiotensin II (formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g., vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Both losartan and its principal active metabolite do not exhibit any partial agonist activity at the AT1 receptor and have much greater affinity (about 1000-fold) for the AT1 receptor than for the AT2 receptor. In vitro binding studies indicate that losartan is a reversible, competitive inhibitor of the AT1 receptor. The active metabolite is 10 to 40 times more potent by weight than losartan and appears to be a reversible, non-competitive inhibitor of the AT1 receptor. Neither losartan nor its active metabolite inhibits ACE (kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin); nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. We investigated the effects of angiotensin II (Ang II) type 1 receptor blockade with losartan on the renin-angiotensin-aldosterone system in hypertensive patients (supine diastolic blood pressure, 95 to 110 mm Hg). Qualifying patients (n = 51) were allocated to placebo, 25 or 100 mg losartan, or 20 mg enalapril. Blood pressure, plasma drug concentrations, and renin-angiotensin-aldosterone system mediators were measured on 4 inpatient days: end of placebo run-in, after first dose, and 2 and 6 weeks of treatment. Plasma drug concentrations were similar after the first and last doses of losartan. At 6 weeks, 100 mg losartan and 20 mg enalapril showed comparable antihypertensive activity. Four hours after dosing, compared with the run-in day, 100 mg losartan increased plasma renin activity 1.7-fold and Ang II 2.5-fold, whereas enalapril increased plasma renin activity 2.8-fold and decreased Ang II 77%. Both drugs decreased plasma aldosterone concentration. For losartan, plasma renin activity and Ang II increases were greater at 2 than at 6 weeks. Effects of losartan were dose related. After the last dose of losartan, plasma renin activity and Ang II changes were similar to placebo changes by 36 hours. These results indicate that long-term blockade of the feedback Ang II receptor in hypertensive patients produces modest increases of plasma renin activity and Ang II that do not appear to affect the antihypertensive response to the antagonist. /Salt not specified/ IL-1beta is a potent proinflammatory, pro-fibrogenetic and pro-athrosclerosis cytokine which has been shown to play an important role in an expanding number of noninfectious, chronic inflammatory conditions including cardiovascular disease, renal fibrosis, rheumatoid arthritis and even type 2 diabetes. Losartan is an angiot

Pharmacodynamics

Losartan is an angiotensin II receptor blocker used to treat hypertension, diabetic nephropathy, and to reduce the risk of stroke. Losartan has a long duration of action as it is given once daily. Patients taking losartan should be regularly monitored for hypotension, renal function, and potassium levels.

Mechanism of action

It has very good absorptive properties.